NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma who Failed Platinum-Containing Chemotherapy or Progressed within 12 Months of Neoadjuvant or Adjuvant Platinum-Containing Chemotherapy

3rd indication approved for Toripalimab in China SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel…

NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma who Failed Platinum-Containing Chemotherapy or Progressed within 12 Months of Neoadjuvant or Adjuvant Platinum-Containing Chemotherapy

3rd indication approved for Toripalimab in China SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel…

Colliers releases first Global Impact Report

Development of full impact position and comprehensive strategy underway for 2021 TORONTO, April 12, 2021 (GLOBE NEWSWIRE) — Colliers (NASDAQ, TSX: CIGI), a leading diversified professional services and investment management company, published its first annual…